| |
-S. cerevisiae Ab Profile
-S. cerevisiae Antibodies
-Saccharomyces cerevisiae Antibody Profile (ASCA)
-Saccharomyces cerevisiae IgG and IgA
-Salicylate, Serum (SALI)
-Salicylic Acid
-Sandimmune®, CSA
-% Sat
-Scl-70
-Scl-70 Antibody
-Scl-70 Autoantibody (SCL7)
-Scleroderma Antibody
-Screening Culture for Group ABeta-Hemolytic Streptococci
-Se, Blood
-Sed Rate
-Sedative Screen (SEHY)
-Sedimentation Rate, Westergren, Whole Blood (SR)
-See Total Iron Binding Capacity Profile Pericardial Fluid Culture
-Selenium, Serum (SELEN)
-Semiquantitative, Urine Sugar Water Test
-Sensitivity
-Serine Protease Inhibitor
-Serotonin (SERO)
-Serotonin Release Assay
-Sertraline (SERTR)
-Serum Electrolytes
-Serum Folate
-Serum Glutamic Oxaloacetic Transaminase
-Serum Glutamic Pyruvate Transaminase
-Serum Hepatitis Marker
-Serum Immunoelectrophoresis
-Serum Immunoglobulins
-Serum Osmolality
-Serum Potassium
-Serum Protein Electrophoresis
-Serum Viscosity
-Sex Hormone Binding Globulin (SEXHB)
-SG, Urine
-SGOT
-SGPT
-SHBG
-Shingles Screen for Immune Status
-Sickle Cell Prep
-Siderophilin
-SIEP
-Silver, Serum (AGBAT)
-Sin Nombre Hantavirus
-Sinequan®
-Sjögren’s Autoantibody Profile (SJO)
-Skeletal Muscle Antibody
|
|
|
|
Print |
| Status Rubella Titer |
| |
| See Rubella IgG Antibody, Immune Status |
Print |
| S. cerevisiae Ab Profile |
| |
| See Saccharomyces cerevisiae Antibody Profile |
Print |
| S. cerevisiae Antibodies |
| |
| See Saccharomyces cerevisiae Antibody Profile |
Print |
| Saccharomyces cerevisiae Antibody Profile |
| |
| Includes: |
IgG and IgA Antibodies |
| |
| CPT: |
86671 (x2) |
| |
| Alternate Name: |
ASCA; S. cerevisiae Antibodies; Saccharomyces cervisiae IgG and IgA; S. cerevisiae Ab profile |
| |
| Methodology: |
EIA |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| < 20.1 Units for each |
| |
| Clinical Utility: |
| Aid in differentiating Crohn’s disease from ulcerative colitis. |
| |
Print |
| Saccharomyces cerevisiae IgG and IgA |
| |
| See Saccharomyces cerevisiae Antibody |
Print |
| Salicylate, Serum |
| |
| CPT: |
80196 |
| |
| Alternate Name: |
Acetylsalicylic Acid; ASA; Aspirin; Salicylic Acid |
| |
| Methodology: |
Endpoint |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
Therapeutic •Analgesic:..........................5-10 mg/dL •Anti-inflammatory:............10-30 mg/dL •Toxic:...............................>30 mg/dL |
| |
| Critical Values: |
| >30 mg/dL |
| |
| Clinical Utility: |
| Used to monitor therapeutic drug levels and to evaluate aspirin toxicity. |
| |
Print |
| Salicylic Acid |
| |
| See Salicylate, Serum |
Print |
| Sandimmune®, CSA |
| |
| See Cyclosporine |
Print |
| % Sat |
| |
| See Total Iron Binding Capacity Profile |
Print |
| Scl-70 |
| |
| See Scl-70 Autoantibody |
Print |
| Scl-70 Antibody |
| |
| See Scl-70 Autoantibody |
Print |
| Scleroderma Antibody |
| |
| See Scl-70 Autoantibody |
Print |
| Scl-70 Autoantibody |
| |
| Includes: |
Scl 70 antibodies |
| |
| CPT: |
86235 |
| |
| Alternate Name: |
• Progressive Systemic Sclerosis Antibod • Scl-70 Autoantibodies • Scleroderma Antibody • Anti-Scl-70 Antibody • Scl-70 Antibody |
| |
| Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
Negative:...................< 20 U/mL Weak Positive:...........20-39 U/mL Moderate Positive:.....40-80 U/mL Strong Positive:..........> 80 U/mL |
| |
| Clinical Utility: |
| Present in 20% to 40% of diffuse scleroderma patients |
| |
Print |
| Screening Culture for Group ABeta-Hemolytic Streptococci |
| |
| See Culture, Throat Group ABeta-Hemolytic Streptococci Only |
Print |
| Se, Blood |
| |
| See Selenium, Serum |
Print |
| Sed Rate |
| |
| See Sedimentation Rate, Westergren, Whole Blood |
Print |
| Sedative Screen |
| |
| Includes: |
•Identification and quantitation of •Amobarbital •Butabarbital •Butalbital •Phenobarbital •Pentobarbital •Secobarbital |
| |
| CPT: |
80100 |
| |
| Methodology: |
Gas Chromatography (GC) |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum OR plasma |
| |
| Container: |
Red top tube, no serum separator OR green top (sodium heparin) tube |
| |
| Reference Range: |
| Dependent on drug and dosage. |
| |
| Clinical Utility: |
| Useful for detecting use of barbiturates and assessing toxicity. |
| |
Print |
| Sedimentation Rate, Westergren, Whole Blood |
| |
| CPT: |
85651 |
| |
| Alternate Name: |
• Erythrocyte Sedimentation Rate • ESR • Sed Rate • Westergren Sedimentation Rate |
| |
| Methodology: |
Westergren |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood |
| |
| Container: |
Black top (sodium citrate) tube filled to black line OR lavender top (EDTA)tube |
| |
| Special Instructions and/or Comments: |
•If the specimen is stored at room temperature, the test can be processed for up to 4 hours after collection. •If the specimen is stored refrigerated, the test can be processed for up to 24 hours after collection. |
| |
| Reference Range: |
•Male <7 years:......................0-9 mm/hour 7 - 51 years:.................0-10 mm/hour >51 years:....................0-20 mm/hour •Female <7 years:......................0-9 mm/hour 7 - 51 years :................0-20 mm/hour >51 years:....................0-30 mm/hour |
| |
| Clinical Utility: |
| Used as a nonspecific marker of inflammation. |
| |
Print |
| Selenium, Serum |
| |
| CPT: |
84255 |
| |
| Alternate Name: |
Se Blood |
| |
| Methodology: |
Inductively Coupled Plasma - Mass Spectrometry (ICP-MS) |
| |
| Testing Schedule: |
Routine, 5 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Royal Blue top trace metal tube, red label |
| |
| Collection: |
NOTE: High concentrations of gadolinium and iodine are known to interfere with most metals tests. If either gadolinium or iodine containing contrast media has been administered, a specimen cannot be collected for 96 hours. |
| |
| Special Instructions and/or Comments: |
•Centrifuge, pour serum into metal free, acid washed vial and freeze. •DO NOT insert a pipette into the serum to accomplish transfer. •DO NOT ream the specimen with a wooden stick. •Specimen will only be accepted in vials labeled with “metal free” labels. |
| |
| Reference Range: |
• 0-2 M...........................45-90 ng/mL • 3-6 M...........................50-120 ng/mL • 7-9 M...........................60-120 ng/mL • 10-12 M.......................70-130 ng/mL • 13 M - 10 Y..................70-150 ng/mL • > 11 Y:.......................95-165 ng/mL |
| |
| Clinical Utility: |
| Useful for Monitoring selenium replacement therapy |
| |
Print |
| Sensitivity |
| |
| See individual culture listings |
Print |
| Serine Protease Inhibitor |
| |
| See Antithrombin III, Activity |
Print |
| Serotonin |
| |
| CPT: |
84260 |
| |
| Methodology: |
LC/MS-MS |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
3 mL frozen whole blood |
| |
| Container: |
Lavender top (EDTA) tube |
| |
| Collection: |
Avoid medications which may affect seroton in concentrations, to include •Reserpine •Methyldopa •MAO Inhibitors •Lithium •Morphine |
| |
| Special Instructions and/or Comments: |
•Transfer whole blood into a Serotonin Transport Tube containing ascorbic acid, mix well, and FREEZEIMMEDIATELY! •Special transport tubes can be requested by contacting our Referral Testing Department at 610-402-5864. •Specimen must be mixed well and frozen immediately. Once frozen, transport specimen submerged in dry ice. •Frozen glass vials are NOT acceptable. Should the client be unable to freeze the specimen immediately the specimen is stable for up to 24 hours when refrigerated in a controlled refrigerated environment. Please note if the specimen was received unfrozen, freeze and document the time at which the specimen is frozen when received at 2024 LS. |
| |
| Reference Range: |
| < 330 ng/mL |
| |
| Clinical Utility: |
| Useful for, in conjunction with, or as an alternative to, 5-HIAA or serum chromogranin A measurements as a first-line test in the diagnosis of carcinoid syndrome.This includes the differential diagnosis of isolated symptoms suggestive of carcinoid syndrome, in particular flushing. As a second-line test (5-HIAA or serum chromogranin A measurement are first-line tests) in the follow-up of patients with known or treated carcinoid tumors. |
| |
Print |
| Serotonin Release Assay |
| |
| See Heparin Antibody, Serotonin Release |
Print |
| Sertraline |
| |
| CPT: |
80229 |
| |
| Alternate Name: |
Zoloft |
| |
| Methodology: |
High Performance Liquid Chromatography (HPLC) |
| |
| Testing Schedule: |
Routine, 5 times per week |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
| Suggested Therapeutic range:.............30-200 ng/mL |
| |
| Clinical Utility: |
Routine therapeutic drug monitoring of the drug is not indicated in most patients. However, in those patients who do not show the expected response to sertraline, measurement of the blood concentration can indicate whether lack of compliance is the cause for treatment failure Clinical monitoring should also be conducted to confirm baseline clearance prior to instituting a new drug regimen. |
| |
Print |
| Serum Electrolytes |
| |
| See Electrolytes, Serum |
Print |
| Serum Folate |
| |
| See Folic Acid, Serum |
Print |
| Serum Glutamic Oxaloacetic Transaminase |
| |
| See Aspartate Aminotransferase, Serum |
Print |
| Serum Glutamic Pyruvate Transaminase |
| |
| See Alanine Aminotransferase, Serum |
Print |
| Serum Hepatitis Marker |
| |
| See Hepatitis B Surface Antigen |
Print |
| Serum Immunoelectrophoresis |
| |
| See IEP/IFE Profile, Serum |
Print |
| Serum Immunoglobulins |
| |
| See Immunoglobulin Profile 1 |
| See Immunoglobulin Profile 2 |
Print |
| Serum Osmolality |
| |
| See Osmolality, Serum |
Print |
| Serum Potassium |
| |
| See Potassium, Serum |
Print |
| Serum Protein Electrophoresis |
| |
| See Protein Electrophoresis, Serum |
Print |
| Serum Viscosity |
| |
| See Viscosity, Serum |
Print |
| SG, Urine |
| |
| See Specific Gravity, Urine |
Print |
| SGOT |
| |
| See Aspartate Aminotransferase, Serum |
Print |
| SGPT |
| |
| See Alanine Aminotransferase, Serum |
Print |
| SHBG |
| |
| See Sex Hormone Binding Globulin |
Print |
| Shingles Screen for Immune Status |
| |
| See Varicella-Zoster IgG Antibody, Immune Status |
Print |
| Sickle Cell Prep |
| |
| See Hemoglobin Electrophoresis |
Print |
| Siderophilin |
| |
| See Transferrin |
Print |
| SIEP |
| |
| See IEP/IFE Profile, Serum |
Print |
| Silver, Serum |
| |
| CPT: |
83789 |
| |
| Methodology: |
Inductively Coupled Plasma- Mass Spectrometry (ICP- MS) |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
7-10 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Royal Blue top trace metal tube, red label |
| |
| Special Instructions and/or Comments: |
•Centrifuge, pour serum into metal free, acid washed vial and freeze. •DO NOT insert a pipette into the serum to accomplish transfer. •DO NOT ream the specimen with a wooden stick. •Specimen will only be accepted in vials labeled with “metal free” labels. |
| |
| Reference Range: |
| <15 ng/mL |
| |
| Clinical Utility: |
| Useful for determination of silver exposure |
| |
Print |
| Sin Nombre Hantavirus |
| |
| See Hantavirus Antibody Profile |
Print |
| Sinequan® |
| |
| See DoxepinSirolimus |
| See Rapamycin |
Print |
| Sex Hormone Binding Globulin |
| |
| Includes: |
Sex horomone binding globulin levels |
| |
| CPT: |
84270 |
| |
| Alternate Name: |
SHBG |
| |
| Methodology: |
Chemiluminescent Immunoassay |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Centrifuge specimen, transfer to plastic aliquot tube and freeze. Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
•Male:..................13-71 nmol/L •Femal:................18-114 nmol/L |
| |
| Clinical Utility: |
| Levels of SHBG are under the positive control of estrogens and thyroid hormones, and are suppressed by androgens. Decreased levels of SHBG are frequently seen in hirsutism, virilization, obese postmenopausal women, and in women with diffuse hair loss. Increased levels may be present in cases of hyperthyroidism, testicular feminization, cirrhosis, male hypogonadism, pregnancy, women using oral contraceptives, and prepubertal children. |
| |
Print |
| Sjögren’s Autoantibody Profile |
| |
| Includes: |
SS-a and SS-b Autoantibodies |
| |
| CPT: |
86235, 86235 |
| |
| Alternate Name: |
Anti-La; Anti-Ro; Anti-SSa; Anti-SSb; SS-a Antibodies; SS-b Antibodies |
| |
| Methodology: |
Enzyme-Linked Immunosorbent Assay (ELISA) |
| |
| Testing Schedule: |
1 time per week |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
Negative:...........................<20 U/mL Weak Positive:..................20-39 U/mL Moderate Posivite:............40-80 U/mL Strong Positive:.................> 80 U/mL |
| |
| Clinical Utility: |
| This panel is used to aid the diagnosis of Sjogren's Syndrome. One or both of the autoantibodies are detected in 80-90% of Sjogren's Syndrome (SS) and 30 - 35% of patients with SLE. SSA and SSB antibodies detected in 96% of patients with primary (SS) and in all patients with SS secondary to RA. SSA and SSB are rarely detected in SS secondary to rheumatoid arthritis, progressive systemic sclerosis and primary biliary cirrhosis. |
| |
Print |
| Skeletal Muscle Antibody |
| |
| See Striated Muscle AutoantibodySkeletal Muscle Biopsy |
| See Histopathology, Muscle BiopsySkin Antibodies |
| See Skin Autoantibody Profile |
Print |
| Skin Autoantibody Profile |
| |
| Includes: |
•ICS autoantibody Autoantibody to intercellular substance (ICS) in pemphigus. •BM autoantibody Autoantibody to basement membrane (BM) in pemphigoid. |
| |
| CPT: |
86255 (x2) |
| |
| Alternate Name: |
Basement Membrane (BM); Cutaneous Immunofluoresecent Antibodies; Intercellular Substances (ICS); Pemphigoid; Pemphigus; Skin Antibodies |
| |
| Methodology: |
Indirect Fluorescent Antibody (IFA) |
| |
| Testing Schedule: |
Routine, Monday-Friday ONLY |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Negative No antibody detected. |
| |
| Clinical Utility: |
| Useful for Confirming a diagnosis of pemphigoid, pemphigus, EBA, or bullous LE and monitoring therapeutic response in patients with pemphigus. |
| |
Print |
| Skin Biopsy Antibodies |
| |
| See Histopathology, Skin Biopsy, Immunofluorescence |
Print |
| Skin Biopsy for Bullous or Collagen Disease |
| |
| See Histopathology, Skin Biopsy, Immunofluorescence |
Print |
| Skin Biopsy for Pemphigoid |
| |
| See Histopathology, Skin Biopsy, Immunofluorescence |
Print |
| Skin Biopsy for Pemphigus |
| |
| See Histopathology, Skin Biopsy, Immunofluorescence |
Print |
| Skin Burn Culture |
| |
| See Culture, Burn Wound |
Print |
| Smooth Muscle Antibody |
| |
| See Smooth Muscle Autoantibody |
Print |
| Smooth Muscle Autoantibody |
| |
| Includes: |
•Smooth Muscle Autoantibody •Reflexed when appropriate Quantitative titer on positive screens |
| |
| CPT: |
86255, Reflexed when appropriate 86256 |
| |
| Alternate Name: |
Anti-Smooth Muscle Antibody; ASMA; Smooth Muscle Antibody, Actin |
| |
| Methodology: |
Indirect Fluorescent Antibody (IFA) |
| |
| Testing Schedule: |
Routine, 2 times per week |
| |
| Report Available: |
3-5 days (may be extended if further dilutions required) |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| Negative titer <1:20 |
| |
| Clinical Utility: |
| Useful in the diagnosis of liver disease. High titers of SMA of anti-active specificities are found in 97% of patients with autoimmune chronic active hepatitis. SMA(non-anti- active) are also found in virus induced liver disease. Absence of SMA and nuclear antibodies argues for non-autoimmune forms of chronic hepatitis. |
| |
Print |
| SNP |
| |
| See Sensory Neuropathy Profile |
Print |
| Sodium, Body Fluid |
| |
| CPT: |
84302 |
| |
| Alternate Name: |
Body Fluid Sodium; Na, Body Fluid |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL body fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
| Not established, must be interpreted with clinical findings. |
| |
Print |
| Sodium, Serum |
| |
| CPT: |
84295 |
| |
| Alternate Name: |
Na+ |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| 135- 146 mEq/L |
| |
| Critical Values: |
•<120 mEq/L •>155 mEq/L |
| |
| Clinical Utility: |
| Used in the evaluation of electrolyte and acid/base balance, dehydration and water balance and water intoxication. |
| |
Print |
| Sodium, 24-Hour Urine |
| |
| See Sodium, Urine |
Print |
| Sodium, Urine Random |
| |
| CPT: |
84300 |
| |
| Alternate Name: |
Na, Urine; Sodium, Urine Sodium |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
Random |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory promptly. |
| |
| Reference Range: |
30-90 mEq/L NOTE For sodium spot samples there is a large diurnal variation in range. |
| |
| Clinical Utility: |
| Used in the evaluation of sodium intake/loss and balance, dehydration and also aids in evaluating renal/adrenal function. |
| |
Print |
| Sodium, Urine 24-Hour |
| |
| Includes: |
•Volume Measurement •Collection Period •Creatinine, Urine •Sodium, Urine |
| |
| CPT: |
81050, 84300 |
| |
| Alternate Name: |
Na, Urine; Sodium, 24-Hour Urine; Urine Sodium |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
Entire 24-Hour urine collection |
| |
| Container: |
Entire 24-Hour plastic urine container, no preservative |
| |
| Collection: |
24-Hour urine collection See special instructions for “24-Hour Urine Collection”, listed under Specimen Collection, Preparation, and Handling Section |
| |
| Special Instructions and/or Comments: |
| Transport to the laboratory promptly. |
| |
| Reference Range: |
•Creatinine, 24 Hour Urine:.........0.8-2.8 g/24 hours •Sodium, Random Urine:............30-90 mEq/L •Sodium, 24-Hour Urine: ...........40-220 mEq/24 hours |
| |
| Clinical Utility: |
| Used in the evaluation of sodium intake/loss and balance, dehydration and also aids in evaluating renal/adrenal function. |
| |
Print |
| Sodium, Vitreous |
| |
| CPT: |
84302 |
| |
| Methodology: |
Potentiometry |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
1-2 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
0.5 mL vitreous fluid |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
| Not established, must be interpreted with clinical findings. |
| |
Print |
| Soluble Liver Antigen Autoantibody |
| |
| CPT: |
83520 |
| |
| Methodology: |
Enzyme Immunoassay (EIA) |
| |
| Testing Schedule: |
Routine, 1 time per week |
| |
| Report Available: |
3-10 days |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| <20.1 Units |
| |
| Clinical Utility: |
| SLA or “Cytokeratin” Autoantibodies are associated with autoimmune hepatitis (AIH), type 2. AIH patients are generally divided into 2 groups based on the presence of specific autoantibodies.AIH type 1 is the more common type of AIH, and is characterized by Antinuclear Antibodies (ANA), Smooth Muscle Autoantibodies (ASMA), and the “perinuclear type” of ANCA. AIH type 2 is characterized by auto antibodies directed against soluble liver antigen (SLA) and liver cytosol antigen (LC-1) - AIH type 1 patients are characteristically negative for SLA and LC-1autoantibodies. Although only about 12-30% of AIH patients have SLA autoantibodies, the presence of these has almost 100% specificity for AIH. |
| |
Print |
| Soma® |
| |
| See Carisoprodol and Metabolite |
Print |
| Somatomedin-C |
| |
| See Insulin-Like Growth Factor-1 |
Print |
| Somophyllin® |
| |
| See Theophylline, SerumSPE |
| See Protein Electrophoresis, Serum |
Print |
| Specific Esterase |
| |
| See Esterase Stain, Naphthol AS-D |
Print |
| Specific Gravity, Body Fluid |
| |
| CPT: |
84315 |
| |
| Alternate Name: |
Fluid, Specific Gravity; Refractometer; Specific Gravity |
| |
| Methodology: |
Refractometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL miscellaneous body fluid (pleural, paracentesis, thoracentesis, etc) |
| |
| Container: |
Red top tube, no serum separator |
| |
| Reference Range: |
| Not established, must be interpreted with clinical findings. |
| |
Print |
| Specific Gravity, Urine |
| |
| CPT: |
81002 |
| |
| Alternate Name: |
SG, Urine; Refractive Index, Urine |
| |
| Methodology: |
Refractometry |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL random urine |
| |
| Container: |
Plastic urine container |
| |
| Collection: |
•First morning specimen is recommended. •Transport to the laboratory within 2 hours of collection. |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| 1.003-1.030 |
| |
| Clinical Utility: |
| Used to evaluate the concentrating ability of the kidneys and general hydration status |
| |
Print |
| SPEP |
| |
| See Protein Electrophoresis, Serum |
Print |
| Spinal Fluid Culture |
| |
| See Culture, Cerebrospinal Fluid |
Print |
| Spinal Fluid Cytology |
| |
| See Cytopathology, Cerebrospinal Fluid |
Print |
| Spinal Fluid Lactate |
| |
| See Lactate, Cerebrospinal Fluid |
Print |
| Spinal Fluid VDRL |
| |
| See VDRL, Cerebrospinal Fluid |
Print |
| Spinal Tap |
| |
| See Cell Count, Cerebrospinal Fluid |
Print |
| Sputum Culture |
| |
| See Culture, Sputum |
Print |
| Sputum Culture for Cystic Fibrosis |
| |
| See Culture, Sputum, Cystic Fibrosis |
Print |
| Sputum Smear for Eosinophils |
| |
| See Eosinophil Smear, Nasal Smear or Sputum |
Print |
| SS-a Antibodies |
| |
| See Sjögren’s Autoantibody Profile |
Print |
| SS-b Antibodies |
| |
| See Sjögren’s Autoantibody Profile |
Print |
| SSDNA Autoantibody |
| |
| See DNA Autoantibody, Single-Stranded |
Print |
| Staclot LA™ |
| |
| See Hexagonal Phase Phospholipid Neutralization |
Print |
| Starch, Fecal |
| |
| CPT: |
89225 |
| |
| Methodology: |
Microscopic/Stain |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
5 gm random stool |
| |
| Container: |
Plastic stool container with lid OR plastic urine container, no preservative |
| |
| Collection: |
• Submit separate samples for each random stool test requested. • Specimens submitted in preservatives are unacceptable. |
| |
| Special Instructions and/or Comments: |
Freeze entire specimen.Once frozen, transport specimen submerged in dry ice. NOTE Specimen must be frozen within 36 hours of collection. |
| |
| Reference Range: |
| Negative |
| |
| Clinical Utility: |
| Useful to access startch excretion |
| |
Print |
| State Newborn Screen |
| |
| See Newborn Screening, State Mandated |
Print |
| Stelazine® |
| |
| See Trifluoperazine |
Print |
| Stone Analysis |
| |
| Includes: |
Analysis (appearance, dimension, composition, interpretation) of kidney or bladder calculi |
| |
| CPT: |
82360 |
| |
| Alternate Name: |
Kidney Stone Analysis |
| |
| Methodology: |
Varies |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
Up to 2 weeks |
| |
| Specimen Requirements: |
| Minimum Volume: |
Renal, urethral, OR bladder calculi |
| |
| Container: |
Clean, dry container |
| |
| Special Instructions and/or Comments: |
| Maintain specimen at room temperature. |
| |
| Reference Range: |
| See report. |
| |
| Clinical Utility: |
| Managing patients with recurrent renal calculi. |
| |
Print |
| Stool Analysis |
| |
| See Occult Blood, StoolStool for Ova and Parasite |
| See Ova and Parasites, Stool |
Print |
| Stool for pH |
| |
| See pH, StoolStool for Routine Culture |
| See Culture, Stool |
Print |
| Stool for WBCs |
| |
| See Leukocytes, Stool |
Print |
| Stool for White Cells |
| |
| See Leukocytes, Stool |
Print |
| Stool Osmolality |
| |
| See Osmolality, Stool |
Print |
| Strep A Antigen, Rapid Screen with Reflex to Culture |
| |
| Includes: |
•Rapid EIA for Group A Strep Antigen •Negative EIA screen reflexed to Culture •Identification if appropriate (additional CPT codes may apply) |
| |
| CPT: |
87430, 87081 See Billing Section for identification and susceptibility CPT codes page. |
| |
| Alternate Name: |
Rapid Group A Beta- Hemolytic Streptococci Antigen See also Culture, Throat, Group A,Beta-Hemolytic Strep Only |
| |
| Methodology: |
Immunoassay (IA) with aerobic bacterial culture if immunoassay is negative. |
| |
| Testing Schedule: |
Routine; STAT testing available |
| |
| Report Available: |
•Rapid Antigen results are available the same day. •Cultures with no beta strep will be reported after1 day. •Cultures with Group A Strep require 1-2 days NOTE Negative rapid Antigen results will be followed up with a throat culture. |
| |
| Specimen Requirements: |
| Container: |
BBL Culture Swab with red cap (BD Cat #30130439).DO NOT use culture swab with gel transport. |
| |
| Collection: |
•Using the sterile swab (or two swabs simultaneously if provided with two), rub the tonsils and pharynx touching any areas of exudate orulceration present.Avoid the tongue and uvula. •Transport Culture swab to the laboratory immediately at room temperature. •DO NOT refrigerate. |
| |
| Reference Range: |
| No beta hemolytic streptococcus group A, C or G isolated. |
| |
| Clinical Utility: |
| The detection of group A strep from a symptomatic patient is usually considered clinically significant. |
| |
Print |
| Strep pneumoniae Antigen |
| |
| See Bacterial Antigen Profile |
Print |
| Strep Screen |
| |
| See Culture, Throat, Group A, Beta-Hemolytic Streptococci Only |
Print |
| Strep Throat Screen |
| |
| See Culture, Throat, Group A, Beta-Hemolytic Streptococci Only |
Print |
| Streptococcal DNase B Antibody |
| |
| See DNase B Antibody |
Print |
| Streptolysin O Antibody |
| |
| CPT: |
86060 |
| |
| Alternate Name: |
Anti-Streptolysin O Antibody; ASL; ASO Titer;ASOT; Group A Strep Antibody Screen; Streptozyme |
| |
| Methodology: |
Rate Nephelometry |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Reference Range: |
| <240 IU/mL |
| |
Print |
| Streptozyme |
| |
| See Streptolysin O Antibody |
Print |
| Striated Muscle Antibody |
| |
| See Striated Muscle Autoantibody |
Print |
| Striated Muscle Autoantibody |
| |
| CPT: |
86256 |
| |
| Alternate Name: |
• Anti-Skeletal Muscle Antibody • Skeletal MuscleAntibody • Striated Muscle Antibody • Striational Muscle Antibody • Striational Autoantibodies |
| |
| Methodology: |
IFA |
| |
| Testing Schedule: |
Routine, 3 times per week |
| |
| Report Available: |
3-5 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| Negative = <1:40 |
| |
| Clinical Utility: |
| Striational antibodies are used to diagnose myopathic disorders and are found in 80% to 100% of patients with myasthenia gravis and thymoma. |
| |
Print |
| Striational Muscle Antibody |
| |
| See Striated Muscle Autoantibody |
Print |
| Strongyloides AB |
| |
| CPT: |
86682 |
| |
| Alternate Name: |
Strongyloides IgG Antibody |
| |
| Methodology: |
ELISA |
| |
| Testing Schedule: |
Routine, daily |
| |
| Report Available: |
5-7 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
1 mL serum |
| |
| Container: |
Gold top (serum separator) tube |
| |
| Special Instructions and/or Comments: |
| Refrigerate |
| |
| Reference Range: |
| <1.0 |
| |
| Clinical Utility: |
| Strongyloides stercoralis is a parasitic nematode found in tropical and subtropical regions. Because of low larval densities in feces, stool examination is a relatively insensitive diagnostic test; serodiagnosis by ELISA offers increased sensitivity. Antibody titers decrease in many patients following treatment. Patients with latent infections, who are immunosuppressed or receiving immunosuppressive therapy, are at risk of life-threatening hyperinfection. |
| |
Print |
| Sucrose Hemolysis Test |
| |
| See Paroxysmal Nocturnal Hemoglobinuria Screen, Whole Blood |
Print |
| Sucrose RBC Hemolysis |
| |
| See Paroxysmal Nocturnal Hemoglobinuria Screen, Whole Blood |
Print |
| Sudan Black B Stain |
| |
| CPT: |
88313 |
| |
| Methodology: |
Manual |
| |
| Testing Schedule: |
Routine, Monday-Friday only |
| |
| Report Available: |
2-4 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL whole blood OR 2 bone marrow films |
| |
| Container: |
Lavender top (EDTA) tube for whole blood |
| |
| Collection: |
Routine venipuncture or bone marrow aspiration |
| |
| Reference Range: |
| Results interpreted by Hematopathologist. |
| |
| Clinical Utility: |
| Used as an aid in the differentiation of leukemias. |
| |
Print |
| Sugar, Fasting |
| |
| See Glucose, Serum or Plasma |
Print |
| Sugar, Quantitative, Urine |
| |
| See Glucose, Urine |
Print |
| Sugar, Semiquantitative, Urine |
| |
| See Reducing Substances, |
Print |
| Semiquantitative, Urine Sugar Water Test |
| |
| See Paroxysmal Nocturnal Hemoglobinuria Screen, Whole Blood |
Print |
| Sulfamethoxazole Drug Level |
| |
| CPT: |
80299 |
| |
| Methodology: |
High Performance Liquid Chematography (HPLC) |
| |
| Testing Schedule: |
Routine |
| |
| Report Available: |
1-2 days |
| |
| Specimen Requirements: |
| Minimum Volume: |
2 mL serum |
| |
| Container: |
Red top tube, no serum separator |
| |
| Special Instructions and/or Comments: |
• Centrifuge, transfer serum to plastic tube and freeze • Once frozen, transport specimen submerged in dry ice. |
| |
| Reference Range: |
| > 50 mcg/mL |
| |
| Clinical Utility: |
| Useful for monitoring therapy to ensure drug absorption, clearance or compliance |
| |
Print |
| Supplemental Newborn Screen |
| |
| See Newborn Screening, Supplemental |
Print |
| Supplemental Screen |
| |
| See Newborn Screening, Supplemental |
Print |
| Sural Nerve |
| |
| See Histopathology, Nerve Biopsy |
Print |
| Surgical Pathology |
| |
| See HistopathologySurgical Pathology Consultation |
| See Histopathology, Frozen Tissue Section Surgical |
Print |
| Specimen Culture |
| |
| See Culture, Tissue, AerobicSurmontil® |
| See Trimipramine Susceptibility |
| See individual culture listings Swan-Ganz Tip Culture |
| See Culture, Catheter Tip |
Print |
| Sweat Chloride Analysis |
| |
| See Chloride, Sweat Synovial Fluid, Cell Count |
Print |
| Synovial Fluid, Crystals |
| |
| See Crystal Examination, Miscellaneous Fluid |
Print |
| Synovial Fluid Culture |
| |
| See Culture, Fluid, Aerobic |
Print |
| Synovial Fluid Cytology |
| |
| See Cytopathology, Fluid |
Print |
| Synovial Fluid, Mucin Clot Test |
| |
| See Mucin Clot Test |
Print |
| Synovial Fluid Profile |
| |
| Includes: |
•Cell Count •Crystals •Mucin Clot •Viscosity |
| |
| CPT: |
89050 , 89051, 89060, 83872,85810, 88107 |
| |
| Alternate Name: |
Fluid Analysis, Synovial Fluid |
| |
| Methodology: |
Manual |
| |
| Testing Schedule: |
Routine, STAT testing available |
| |
| Report Available: |
1 day |
| |
| Specimen Requirements: |
| Minimum Volume: |
1.5 mL fluid in each tube |
| |
| Container: |
Lavender top (EDTA) tube AND red top tube, no serum separator |
| |
| Reference Range: |
| See individual test listings. |
| |
| Clinical Utility: |
| Used in the evaluation of inflammatory and infectious disorders of joints and in the evaluation of joint pathology and trauma. |
| |
Print |
| Synovial Fluid, Viscosity |
| |
| See Viscosity, Fluid |
Print |
| Syphilis Screen |
| |
| See Rapid Plasma Reagin |
Print |
| Syphilis Screening Test |
| |
| See Rapid Plasma Reagin |
Print |
| Syphilis Serology |
| |
| See Rapid Plasma Reagin |
Print |
| See Total Iron Binding Capacity Profile Pericardial Fluid Culture |
| |
| See Culture, Fluid, Aerobic |
|